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Introduction
Gaucher disease (GD) is an autosomal recessive condition that 
is caused by defective glucocerebrosidase (GCase) enzyme. 
GCase (GBA gene) normally functions to breakdown lipids in 
the lysosomes and mutations in GCase cause accumulation of 
its substrate, glucoceramide (GlcCer)1. These mutations result in 
characteristic engorged macrophages, known as Gaucher mac-
rophages (GMs) or ‘Gaucher cells’2. The GlcCer buildup in 
macrophages manifests as a multi-systems disorder, with signs 
such as hepatosplenomegaly, anaemia, thrombocytopenia, and 
bony impairments, reviewed by 3. GD is common in Ashkenazi 
Jewish populations, although the disorder is pan-ethnic4. GD has 
been historically divided into three types, based on the severity of 
clinical features and neurological involvement3,5. Type I GD is 
classically defined as non-neuropathic, although neurological 
deficits have been described in some of these patients6 including 
Parkinsonism7–10. Type II disease usually begins in infancy, with 
severe neurological involvement. Type III GD is an extended 
form of type II, also with neuropathic problems but patients live 
into adolescence and adulthood largely due to the development of 
enzyme replacement therapy (ERT)3,5.
It is now apparent that there is a strong genetic connection 
between Gaucher and Parkinson’s disease (PD). Studies have 
shown that in large multi-center patient cohorts, patients with 
PD have an increased incidence of carrying GBA mutations11–14, 
including 3% of sporadic PD patients and up to 15% in Ashkenazi 
Jewish populations with PD15. Thus, we now know that heterozy-
gote GBA mutations are the single commonest genetic risk factor 
for familial16 and sporadic PD; leading to a more rapid progression 
of PD with an early onset dementia12–14.
The cellular pathology in lysosomal storage disorders (LSD) 
is centered around the misfolding of GCase and lysosomal 
dysfunction. Lysosomes have also been implicated in PD and 
several other neurodegenerative disorders including Alzheimer’s 
disease and Huntington’s disease17,18, suggesting that similar 
underlying defects in autophagy and lysosomal dysfunction may 
link the pathophysiology of PD to GD19. The accumulation of 
substances in the lysosome impacts on their function and other 
intracellular pathways, resulting in secondary changes such as 
an impairment of autophagy20. Lysosomal and autophagy impair-
ments are apparent in cell line models, mouse models and in 
post-mortem tissue from PD patients. In PD mice models, com-
ponents of lysosomal function are affected, causing a reduction in 
lysosomal number and accumulation of autophagosomes21. 
Genetic mutations causing PD have also implicated the lysosome; 
these include ATPase Type 13A2 (ATP13A), which encodes a 
lysosomal ATPase, maintains lysosomal pH, and inhibits α-syn 
misfolding22. α-synuclein aggregation in the lysosome, as seen in 
PD and LSD, may in turn accelerate its own aggregation.
In this study, we sought to investigate autophagic function 
and GCase enzyme function using cells derived from patients. 
We tested patients with PD with and without GBA mutations as 
well as individuals with GD. We sought to define the extent of 
reduced GCase enzyme activity in all cases, and how this relates 
to autophagic flux. The activity of three other housekeeping 
lysosomal enzymes was also looked at, to see the extent to which 
the enzyme defect was specific.
Methods
Patients and fibroblast cell lines
Fibroblasts were derived from dermal skin biopsies. In Table 1 
the characteristics of the 13 patient derived and 4 healthy control 
fibroblast are summarised. Written informed consent was taken 
from each participant, and the ethics for this study was approved 
by the Cambridge Central Research Ethics Committee (REC09/
H0311/88). HFL1 (ATCC-CCL-153) cells were obtained from 
the American Type Culture Collection (ATCC), expanded in 
standard fibroblast medium and used as controls. Skin biopsies 
were taken from patients with:
(i)     Both GD and PD (homozygous, PD/GD), n=3
(ii)     PD with one GBA mutation (heterozygous, PD GBA), 
n=3
(iii)   PD with no GBA mutations, idiopathic PD (iPD), n=3
(iv)   Healthy controls, n=4
(v)    GD only (homozygous), with no PD (GD), n=4
Western blot experiments
To detect protein expression, samples obtained from the lysed 
cells were loaded on to a 4–12% SDS-PAGE gel (Invitrogen). 
Cells were harvested using either Radioimmunoprecipitation 
assay buffer (RIPA), containing 1.0% sodium dodecyl sul-
fate (SDS), 0.5% Sodium Deoxycholate, 0.1% Triton X 100, 
150 mM NaCl, 50 mM Tris-HCl pH 8.0 and protease inhibi-
tors, or NP40 (Nonidet P40) buffer containing 150 mM NaCl, 
50 mM Tris-HCl pH 8.0, NP-40 1.0% and protease inhibitors. The 
samples were sonicated at 1 second intervals for 10 secs, cen-
trifuged at 20,000 g for 20 minutes at 4°C and the supernatant 
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was snap frozen and stored at -80°C. The total protein 
concentration was quantified by a BCA assay (Thermo Scien-
tific). The gel was run in 3-(N-morpholino) propanesulfonic acid 
(MOPS) buffer at 100 V, 40mA for 1 hour. The proteins on the 
SDS gel were transferred to a polyvinylidene fluoride (PVDF) 
membrane at 30 V, 100 mA for 2 hours. Then the membrane was 
incubated with Ponceau red to detect the proteins before being 
blocked (room temperature (RT), 1 hr) with 5% w/v semi skimmed 
milk, 1% bovine serum albumin (BSA) PBS with tween 
(PBS-T 0.3% v/v) and incubated with primary antibodies 
GBA(GCase) rabbit polyclonal, sigma (G4046) 1:1000, LC3 rab-
bit polyclonal New England Biolabs (NEB) (2775S) 1:1000, 
and actin rabbit polyclonal Abcam ab8229 1:1000 overnight 
at 4°C. Following washes in PBS-T (3 X 5 min), horseradish 
peroxidase labeled secondary anti rabbit antibodies (Bio-Rad 
1662408EDU) were applied at 1:10,000 dilution in 5% milk, 
1% BSA (room temperature, 1 hr). Membranes were washed 
again with PBS-T and protein bands visualized by chemilumi-
nescence (Thermo Pierce) estimating band molecular weights 
relative to standard protein markers in the range of 10–120 kDa 
(Novex® Sharp Pre-stained Protein Standard, Life Technologies). 
Protein bands were quantified by densitometry using Image J 
(Fiji) software.
Immunocytochemistry for localisation of intracellular GBA 
proteins
The cellular localisation of the GBA protein in dermal fibroblasts 
was investigated using antibodies against GBA (Sigma, G4046, 
rabbit polyclonal 1:50) and Lamp1 (Abcam, ab25630, mouse 
monoclonal 1:50). Fibroblasts were grown to 50,000 cell/well 
confluency on 0.1% gelatin coated covers-slips in 24-well plates 
overnight in DMEM containing 10% FBS, and 1% penicillin/ 
streptomycin (pen/strep) and fixed in 4% PFA for 30 minutes. 
Cells were washed twice with PBS, blocked in PBS, 10% FBS 
and 0.2% Triton and incubated for 1 hour at room temperature. 
After this the cells were then incubated overnight at 
4°C with the relevant primary antibody (GBA (Sigma, G4046, 
rabbit polyclonal 1:50) and Lamp1 (Abcam, ab25630, mouse 
monoclonal 1:50)) in PBS, 0.2% Triton and 2% FBS. The 
cells were washed three times with PBS the following morn-
ing and incubated with the secondary antibodies (goat anti rab-
bit (green) and goat anti mouse (red) antibodies (Bio-Rad) were 
applied at 1:10,000 dilution in PBS, 0.2% Triton and 2% FBS 
in the dark for 2 hours at room temperature and washed with PBS 
three times for 5 minutes each and stained with Hoescht 1mg/ml 
in PBS for 15 minutes at room temperature in the dark. The cells 
were then washed with PBS 3 times for 5 minutes and imaged 
on a confocal microscope. In each well 10 fields of view were 
captured and this was repeated in triplicate.
Bafilomycin assay
The dermal fibroblasts were seeded and grown at 
a density of 72,000 cells per well in 24-well plates overnight 
in DMEM with 10% FBS and 1% pen/strep. Bafilomycin A1 
from Sigma-Aldrich (B1793) was used at a concentration of 
0.1 mM and added to the cells for 2 hours, this concentra-
tion was derived from titrations of Bafilomycin A1 and 0.1 mM 
and found to be the concentration best tolerated by the cells. 
The cells were either treated with 1) Bafilomycin A1 alone, 
2) Bafilomycin A1 and starvation medium (Hanks’ Balanced Salt 
Solution (HBBS) with 5% Sodium Bicarbonate) 3) starvation 
alone and 4) untreated cells as a control. The cells were incubated 
for 2 hours at 37°C and then washed twice with ice cold PBS. 
To harvest, the cells were incubated with prechilled NP-40 lysis 
buffer for 30 minutes with shaking at 4°C. The cells were then 
collected and spun at 20,000 g for 15 minutes, the supernatant 
was snap frozen and stored at -80°C until processed for 
western blotting analysis.
Lysosomal activity assays
Cell preparation. The enzyme activity assays were performed 
on fibroblasts harvested from 24-well plates. Cells were seeded 
at a density of 100,000 cells per well in DMEM containing 
10% FBS and 1% pen/strep. After 24 hours the cells were har-
vested in ice-cold lysis buffer specific to each reaction described 
below. The lysate was spun for 20 minutes at 20,000 g at 4°C. 
The cell pellet was then resuspended in lysis buffer and soni-
cated for 1 minute, while keeping the sample on ice. A BCA assay 
(Thermo Fisher) was performed to quantify protein concentration.
Table 1. Clinical and demographic information for the patient 








PD001 F/58 R463C/R463C GD Type I/ PD No
GD005 M/56 L444P/R463C GD Type I/ PD No
GD004 F/50 N370S/L444P GD Type I/ PD No
Parkinson’s disease GBA carriers (PD GBA)
PD002 F/64 N370S/WT PD Yes
PD003 M/69 E326K/WT PD Yes
PD004 M/57 E326K/WT PD Yes
Parkinson’s disease normal GBA (iPD)
PD005 F/68 WT/WT PD No
PD006 F/66 WT/WT PD Yes
PD007 M/65 WT/WT PD No
Healthy controls (Controls)
C001 F/54 WT/WT No neurological 
disease
No
C002 M/57 WT/WT No neurological 
disease
No
C003 M/72 WT/WT No neurological 
disease
No




GD002 F/58 N370S/? GD Type I Yes
GD006 M/66 N370S/N370S GD Type I Yes
GD008 M/68 N370S/L444P GD Type I No
GD009 M/69 N370S/? GD Type I No
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Glucocerebrosidase activity assay
For the GCase activity assay, cells were harvested in lysis 
buffer containing 30 mM Citrate Phosphate buffer pH 5.5, 
0.65% Sodium Taurochlorate and 0.65% triton-X 100. 
Enzyme activity was measured using 4-Methylumbelliferyl 
(4MU) β-D-glucopyranoside, Sigma (M3633), as the substrate in 
running buffer containing 30 mM Citrate Phosphate buffer and 
0.6% Sodium Taurochlorate pH 4.4 (to inhibit GCase 2 and 
3). Each well in a 96 well black microplate, contained 20 μg 
(for each sample ~20 μl of protein and 30 μl of buffer) of sam-
ple protein, 75 μl running buffer and 25 μl of 15 mM sub-
strate (which was made up immediately before the assay at 
59.15 mg/ml in Dimethyl sulfoxide (DMSO) and diluted 
1/10 in running buffer and kept in the dark). Each assay was 
repeated in triplicate for each cell sample. The sample alone 
was added in triplicate as a blank and also, the buffer with the 
substrate alone was added as a blank. The samples were incu-
bated for 1 hour at 37°C and the reaction was stopped using 100 μl 
of 0.2 M Glycine pH 10.5. The fluorescence was read on the 
FLUOstar Omega plate reader at excitation 355 nm and 
emission 460 nm.
Hexosaminidase activity assay
Total hexosaminidase activity was measured using fibroblasts 
harvested with lysis buffer containing 0.01 M Citrate phosphate 
buffer, pH 4.4, and 0.2 M Na2HPO4. A solution of 4 μg cell lysate 
(for each sample of ~10 μl of protein), 95 μl of 0.01 M Citrate 
Phosphate buffer and 20 μl of 2.5 mM 4-MU N-acetyl-b-D- 
glucosaminide, Sigma (M2133), in 0.01 M Citrate phosphate 
buffer was added to each well, the assay was performed in tripli-
cate and blanks were included in lysate alone and a separate blank 
(buffer and substrate alone). The reaction ran for 20 minutes 
at 37°C and was stopped by adding 100 μl of 0.17 M Glycine 
pH 9.8 (made up from 2.5 g glycine and 3.6 g Na2CO3). The 
activity was measured on the FLUOstar Omega plate reader 
at excitation 360 nm and emission at 415 nm.
Galactosidase activity assay
To measure α-galactosidase activity, 15 μg of cell lysate (each 
sample contained ~20 μl of protein and 30 μl of buffer), was 
incubated with 75 μl 0.2 M Citrate Phosphate buffer pH 4.4 
and 20 μl of 10 mM 4-MUl α-D-galactopyranosidase, Sigma 
(M7633). This cell lysate solution was added to each well, the 
assay was performed in triplicate and blanks included lysate 
alone and a separate blank (buffer and substrate alone). The reac-
tion was incubated for 30 minutes at 37°C and stopped by adding 
100 μl of 0.17 M Glycine pH 9.8. The activity was measured on 
the FLUOstar Omega plate reader at excitation 360 nm and 
emission at 415 nm.
Mannosidase activity assay
To measure mannosidase activity, 15 μg of cell lysate (for each 
sample ~20 μl of protein and 40 μl of buffer), was incubated 
with 50 μl of 0.2M Citrate Phosphate buffer pH 4.4 and 15 μl of 
5 mM 4-MU α-D-mannopyranoside, Sigma (M3657). This 
cell lysate solution was added to each well, the assay was 
performed in triplicate and blanks included lysate alone and 
a separate blank (buffer and substrate alone). The reaction 
was incubated for 20 minutes at 37°C and stopped by adding 
100 μl of 0.17M Glycine pH 9.8. The activity was measured 
on the FLUOstar Omega plate reader at excitation 360 nm 
and emission at 415 nm.
Gold nanoparticle analysis
The fibroblasts were plated at a density of 50,000 cells/well on 
0.1% gelatin coated coverslips and placed in a 24-well plate. 
The cells were grown over night in DMEM with 10% FBS and 
1% pen/strep. The following day Gold nanoparticles were added 
to the cells (AuNPS). The cells were incubated with the AuNPS 
for 24 hours and then washed with cell culture medium to 
remove the AuNPS. After 16 hours the cells were fixed using 
4% formaldehyde and imaged on a brightfield microscope.
Statistical analysis
All analysis was performed using SPSS version 20.1 (IBM). 
Normality for all the variables was tested using a one-sample 
Kolmogorov–Smirnov tests. Variables which did not follow a 
normal distribution, were log transformed and retested 
for normality. Non-parametric variables were compared with a 
Mann-Whitney U-test or Kruskal Wallis test. Parametric vari-
ables were compared with a t-test or ANOVA. Bonferroni post 
analysis was applied. Each experiment was repeated a minimum 
of three times.
Results
GCase activity is specifically decreased in patient 
fibroblasts carrying a GBA mutation
We started by assessing enzyme activity as an indication of 
overall lysosomal health and the extent to which this is restricted 
to GCase activity. A panel of lysosomal enzymes were screened 
for activity levels and included GCase, α-galactosidase, hexosami-
nidase and mannosidase. The enzyme activity was assessed in all 
the patient and healthy control fibroblast lines (n=17), and then 
grouped in to their respective disease phenotypes, based on 
GBA genotype for the analysis. GCase activity was found not 
surprisingly to be significantly lower in the PD GBA, GD and 
PD/GD compared to controls. In contrast, the iPD group was not 
significantly different compared to any other groups (Figure 1A 
and Dataset 1). There was no significant difference seen in the 
other lysosomal enzymes that were looked at (Figure 1 B–D) and 
Dataset 1).
Endogenous GCase protein expression was assessed by western 
blot to check if there were differences in the protein concentra-
tion between the lines (n=17). The PD/GD skin fibroblasts had 
significantly lower GCase protein compared to control, and iPD. 
There was no significant difference seen between GD, PD GBA 
and the HFL1 (Figure 1E and Dataset 1). Fluorescence immunos-
taining revealed that the endogenous GCase and Lamp1 protein 
co-localised in the control lines but this was not the case in the 
PD/GD lines (Figure 1F and Dataset 1).
We then measured lysosomal function by looking at the 
uptake of gold nanoparticles (AuNP), and did not find any 
significant difference when comparing all cell lines (Figure 1G 
Dataset 1). Taken together, our result show a decrease in 
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Figure 2. Autophagy assay in patient fibroblasts. (A, B) Western blot of LC3IIb and GBA for all patient lines. Ratio of LC3 IIb/actin for control 
(NT) (0.41 ± .14) compared to (B+S) (1.06 ± 0.20) (p=0.053), iPD (NT) (0.17 ± .07) compared to (B+S) (1.13 ± 0.32) (p=0.032). This was also 
true for PD/GD (NT) (0.03 ± 0.01) compared to (B+S) (0.74 ± 0.09) (p=0.048), PD GBA (NT) (0.50 ± 0.07) compared to (B+S) (0.95 ± 0.21).
GD (NT) (0.86 ± 0.23) compared to (B+S) (0.54 ± 0.49) (p>0.05). Optical density of western blot bands was measured in Image J. (C) Data 
was analysed by ANOVA and Bonferroni post hoc test. Analysis was repeated in three independent experiments for each cell line. Data are 
presented as mean ± s.e.m.
GCase levels and activity in GD and PD patients carrying GBA 
mutations, compared to iPD and healthy donors. However, the 
lysosomal basal function and content are not affected.
Autophagy is affected in GD and PD GBA patient fibroblasts
Autophagy has a role in quality control in the cell, and to 
examine this we looked at autophagosome maturation as 
a measure of autophagic flux in the patient fibroblasts (n=17). 
We first investigated the autophagosome content by measur-
ing the ratio of LC3IIb over total actin, in cells with or without 
Bafilomycin A1 treatment followed by starvation. Bafilomy-
cin A1 is a specific inhibitor of vacuolar (H+)-ATPases, and 
a blocker of autophagosome-lysosome fusion. If the cell has a 
well-regulated autophagic flux, Bafilomycin A1 should increase 
LC3IIb without any starvation. If the cell has normal basal flux, 
starvation should increase LC3IIb, due to activation of autophagy. 
Using a combined starvation and Bafilomycin A1 treatment 
should produce the maximum amount of autophagosomes possible 
under these starvation conditions.
In light of this, autophagic flux was found to be elevated 
following treatment with Bafilomycin A1 and starvation in con-
trol, iPD and PD/GD fibroblasts (Figure 2 A–C and Dataset 2). 
In the GD and PD GBA lines, Bafilomycin A1 treatment had no 
effect on LC3IIb expression levels, indicating that autophagic 
flux was impaired in these cells (Figure 2 and Dataset 2).
Dataset 1. Raw data underlying the results presented in Figure 1
http://dx.doi.org/10.5256/f1000research.12090.d178244
Figure 1A. GCase assay raw data and statistics.
Figure 1B. α-galactosidase assay raw data and statistics.
Figure 1C. Hexominidase assay raw data and statistics.
Figure 1D. Mannosidase assay raw data and statistics.
Figure 1E. Western blot GCase raw data, blots and statistics.
Figure 1F. Immunocytochemistry fibroblasts were stained for GCase 
(green), Lamp1 (red) and DAPI (blue). Representative images of 
control and PD/GD lines.
Figure 1G. Gold nanoparticles, images, raw data and statistics.
Dataset 2. Raw data underlying the results presented in Figure 2
http://dx.doi.org/10.5256/f1000research.12090.d178246
Figure 2A. Western blots for autophagy assay with iPD, PD GBA, 
PD/GD and control.
Figure 2B. Western blots for autophagy assay with GD.
Figure 2C. Autophagy assay statistics.
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Discussion
Our results show, for the first time in a large variety of PD/GD 
patient fibroblasts that the only lysosomal enzyme affected by 
GBA mutations is GCase. This finding is consistent with other’s 
work, who have shown GCase to be impaired in fibroblasts from 
GD and PD patients although in smaller patient numbers23–26. 
However we have now extended these findings to show that 
GCase is also abnormal in fibroblasts from patients with PD/GD 
and normal in iPD fibroblasts. We also found that the impair-
ments are not due to low protein amounts in line with other 
studies24,25. This is in contrast with findings in brain post mor-
tem tissue, where GCase amounts have been reported to be 
decreased in both PD GBA and iPD cases27. In the case of 
PD/GD and GD the GCase protein and activity was reduced 
which was expected, however, in the PD GBA the protein 
amount was not reduced but the activity was reduced in this 
case, this leads us to believe in the case of PD GBA there is an 
additional factor, outside the GCase protein, causing pathology 
in these cells which could lead to dysfunction. In contrast to 
other studies, we did not find that the iPD line had significantly 
lower GCase activity compared to controls, although we were 
looking at fibroblasts rather than specific neuronal cells.
The screening of such a large number of GBA carriers with PD 
and GD, using a panel of lysosomal enzymes has not been pre-
viously undertaken. During this screening we found that there 
were no impairments in any other lysosomal enzymes measured 
besides GCase. These findings contradict published work which 
have reported that Hexosaminidase is elevated in PD GBA, GD 
and healthy GBA carriers fibroblasts24. However, in this paper 
the enzyme activity was not directly measured, and the amount 
was determined by western blot, thus the protein amount may be 
elevated, but the specific activity may not be impaired.
In terms of looking at autophagic function, we used both 
Bafilomycin A1 and starvation treatments and observed a normal 
LC3IIb level in the PD/GD, iPD and control lines. However, in 
the case of the PD GBA and GD lines there was no increase in 
LC3IIb flux upon treatment. Most of the GD lines had N370S 
mutations and the PD GBA lines were carriers of N370S and 
E326K. Our results are in agreement with recent publications 
that found impaired autophagic flux was apparent in fibroblasts 
from a GD patient with homozygous L444P mutations28 and in 
cases with compound heterozygous (N370S/L444P) mutations29. 
However, other studies have found no impairment in autophagy, 
but these GD patients had Saposin C, not GBA, mutations30.
All of the PD/GD lines in our study were compound hetero-
zygous and two out of the three cases included L444P. These 
cases had normal autophagic flux, and this was the first study to 
assess autophagy in patients with both diseases. It may be 
that having both diseases together also impacts on autophagy, 
but autophagic function differs depending on the GBA muta-
tion or cell type studied. There are mixed findings in relation to 
autophagy in PD depending on the model being tested. 
Autophagy has been found to be increased in fibroblasts from 
patients with LRRK2 mutations31, but in cell lines it is decreased 
when α-synuclein is overexpressed32. Autophagy as also been 
found to be impaired in iPS derived DA neurons from a PD 
patient with GBA mutations33,34. In our study, autophagic flux was 
normal in iPD patients but abnormal in the PD GBA lines. This 
could be further assessed by correcting the GBA mutation using 
CRISPR/Cas9 gene editing to see if the impairment in autophagy 
is dependent on GBA gene status. In addition it may be that 
GCase activity and autophagy are affected by mitochondrial 
function, which has been implicated in PD GBA previously35, but 
as of yet, not extensively studied. Another factor to consider is 
that the affected GCase in GBA related PD, may be in the wrong 
location such as trapped in the ER, which has previously been 
observed to occur24.
In summary, the GBA mutated patient fibroblast lines had 
impairments of 20–60% GCase activity compared to controls. 
These diseased cells had normal lysosomal function, with inde-
pendent lysosomal uptake. However, PD GBA and GD lines 
display abnormal autophagy. Our results from these genetically 
relevant patient cell models provide evidence that GBA mutations 
could lead to impaired GCase and autophagic function, which 
may translate to CNS neurons and thus clinical expression and 
progression. If so, this cell model could be used in novel drug 
development.
Data availability
Dataset 1: Raw data underlying the results presented in 
Figure 1.
Figure 1A. GCase assay raw data and statistics.
Figure 1B. α-galactosidase assay raw data and statistics.
Figure 1C. Hexominidase assay raw data and statistics.
Figure 1D. Mannosidase assay raw data and statistics.
Figure 1E. Western blot GCase raw data, blots and statistics.
Figure 1F. Immunocytochemistry fibroblasts were stained for 
GCase (green), Lamp1 (red) and DAPI (blue). Representative 
images of control and PD/GD lines.
Figure 1G. Gold nanoparticles, images, raw data and statistics.
DOI, 10.5256/f1000research.12090.d17824436
Dataset 2: Raw data underlying the results presented in 
Figure 2.
Figure 2A. Western blots for autophagy assay with iPD, PD GBA, 
PD/GD and control.
Figure 2B. Western blots for autophagy assay with GD.
Figure 2C. Autophagy assay statistics.
DOI, 10.5256/f1000research.12090.d17824637
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 The major point of concern is the physiological relevance of the cell models studied. Stating the
obvious, since both PD and GD have neurological components, it would have been more
appropriated to reprogram the fibroblasts in iPSCs and then convert these in the relevant cell type







Interestingly, the authors show that mutations to the GCase gene affect both enzymatic activity
(Figure 1A) and amount of protein in PD/GD (Figure 1E - Maybe also in other GBA context, but the
statistical power is too low to discern this aspect). Since the first can be a consequence of the
latter, as a mere suggestion, it would be of interest to investigate this aspect in more detail maybe






To this point, the authors state in the discussion about the GCase activity in PD/GD “We also found
that the impairments are not due to low protein amounts in line with other studies”. As far as this
reviewer understand, there is a significant difference between PD/GD and controls as indicated in









The most obscure point to this reviewer is the fact that PD/GD fibroblasts carrying
homozygous mutation in DBA show reduced enzymatic activity but normal autophagic flux
when PD GBA and GD (carrying similar mutations) have abnormal flux. Could the authors
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when PD GBA and GD (carrying similar mutations) have abnormal flux. Could the authors
























The patient-derived cell lines are actually 13 and not 17 since 4 are derived from healthy














In Figure 1A, multiple bands are visible in the WB. It is not clear which band is accounted for






Figure 1F will benefit from a colocalisation plot and quantification. It is not clear how many
cells have been recorder for this phenotype.
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Acronyms are first presented in the method session. Since many readers do not take the




Figure 2C is missing legend for the color-coding. Although, is the same as previous figure, a













The antibody used for LC3 WB usually recognizes both the LC3II and LC3IIb form of the
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